Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non‐small cell lung cancer patients with neoadjuvant immunotherapy

Neoadjuvant immunotherapy has significantly changed the therapeutic approach for treating patients with surgically resectable non‐small cell lung cancer (NSCLC). Here, peripheral blood inflammation‐based biomarkers as well as previously less focused eosinophil fraction, modified Glasgow prognostic score (mGPS), and prognostic nutritional index (PNI) were systematically included to comprehensively analyze their potential in predicting neoadjuvant immunotherapy efficacy and prognosis. We enrolled 189 patients (94 in training and 95 in validation cohorts) with stage I–III B surgically resectable NSCLC treated with neoadjuvant immunotherapy from the National Cancer Center of China. Baseline and post‐treatment eosinophils fraction, neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), systemic immune‐inflammation index (SII), monocyte‐to‐lymphocyte ratio (MLR), PNI, mGPS, and their changes were calculated and analyzed for correlation with neoadjuvant immunotherapy efficacy and prognosis. In patients in the major pathological response (MPR) group, the post‐treatment eosinophil fraction was significantly high, and NLR, PLR, SII, and MLR were significantly lower compared to the non‐MPR group in both the training and validation cohorts. The receiver operating characteristic curve showed that post‐treatment, eosinophil fraction and SII and their changing were two of the most important factors. Univariate and multivariate logistic regression analyses showed that post‐treatment eosinophil fraction, SII, mGPS, and ΔSII could independently predict MPR in patients treated with neoadjuvant immunotherapy. Survival analysis showed a significant correlation between high post‐treatment NLR, PLR, SII, mGPS, and their changes in ΔNLR and ΔSII elevation with poor overall survival and event‐free survival of patients. Our results suggest that inflammatory biomarkers could predict the patient's response to neoadjuvant immunotherapy and prognosis.

[1]  V. Grünwald,et al.  Integrating On-Treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma , 2023, JAMA oncology.

[2]  Jingling Xue,et al.  Systemic immune-inflammation index predicts prognosis of cancer immunotherapy: systemic review and meta-analysis. , 2022, Immunotherapy.

[3]  Y. She,et al.  The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study , 2022, Cancer Immunology, Immunotherapy.

[4]  E. Otsuji,et al.  Absolute lymphocyte count and C-reactive protein-albumin ratio can predict prognosis and adverse events in patients with recurrent esophageal cancer treated with nivolumab therapy , 2022, Oncology letters.

[5]  V. Velculescu,et al.  Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy , 2022, Journal for ImmunoTherapy of Cancer.

[6]  N. Girard,et al.  Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. , 2022, The New England journal of medicine.

[7]  R. Autorino,et al.  Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette–Guerin Immunotherapy , 2022, Diagnostics.

[8]  J Zhang,et al.  Real-world clinical outcomes of neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancer. , 2022, Lung cancer.

[9]  S. Peters,et al.  SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Bhide,et al.  On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy , 2021, Journal for ImmunoTherapy of Cancer.

[11]  C. Sternberg,et al.  Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort , 2021, ESMO open.

[12]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[13]  V. Seshan,et al.  Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors , 2021, Nature Communications.

[14]  R. López-López,et al.  Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy , 2020, Cancer Immunology, Immunotherapy.

[15]  I. Wistuba,et al.  Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. , 2020, The Lancet. Oncology.

[16]  M. Lanuti,et al.  Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. , 2020, The Lancet. Oncology.

[17]  F. Tan,et al.  Preoperative systemic immune-inflammation index and prognostic nutritional index predict prognosis of patients with pulmonary neuroendocrine tumors after surgical resection , 2020, Annals of translational medicine.

[18]  Fen Liu,et al.  Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors , 2020, Cancer Immunology, Immunotherapy.

[19]  Yibo Gao,et al.  Neoadjuvant PD-1 inhibitor (Sintilimab) in Non-Small Cell Lung Cancer. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  J. Utikal,et al.  Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors , 2020, Oncoimmunology.

[21]  K. Syrigos,et al.  Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. , 2019, The New England journal of medicine.

[22]  Jingjing Liu,et al.  Systemic immune‐inflammation index, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio can predict clinical outcomes in patients with metastatic non‐small‐cell lung cancer treated with nivolumab , 2019, Journal of clinical laboratory analysis.

[23]  N. Sunaga,et al.  Post-treatment Glasgow Prognostic Score Predicts Efficacy in Advanced Non-small-cell Lung Cancer Treated With Anti-PD1 , 2019, AntiCancer Research.

[24]  James J. Lee,et al.  Activated Eosinophils Exert Antitumorigenic Activities in Colorectal Cancer , 2019, Cancer Immunology Research.

[25]  Arnaud Boyer,et al.  Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer. , 2018, Journal of thoracic disease.

[26]  S. Nomura,et al.  Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab , 2018, International Journal of Clinical Oncology.

[27]  M. Berry,et al.  Surgical Outcomes After Neoadjuvant Chemotherapy and Ipilimumab for Non-Small Cell Lung Cancer. , 2017, The Annals of thoracic surgery.

[28]  Yu-suo Tong,et al.  Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer , 2017, Journal of Translational Medicine.

[29]  S. Cai,et al.  Systemic immune-inflammation index for predicting prognosis of colorectal cancer , 2017, World journal of gastroenterology.

[30]  T. Yano,et al.  Comparison of the prognostic values of preoperative inflammation-based parameters in patients with breast cancer , 2017, PloS one.

[31]  Jinming Yu,et al.  Prognostic significance of the lymphocyte-to-monocyte ratio and the tumor-infiltrating lymphocyte to tumor-associated macrophage ratio in patients with stage T3N0M0 esophageal squamous cell carcinoma , 2017, Cancer Immunology, Immunotherapy.

[32]  N. Kim,et al.  Impact of the prognostic nutritional index on the recovery and long-term oncologic outcome of patients with colorectal cancer , 2017, Journal of Cancer Research and Clinical Oncology.

[33]  W. Guo,et al.  Dynamic change of the systemic immune inflammation index predicts the prognosis of patients with hepatocellular carcinoma after curative resection , 2016, Clinical chemistry and laboratory medicine.

[34]  A. Ribas,et al.  Combination cancer immunotherapies tailored to the tumour microenvironment , 2016, Nature Reviews Clinical Oncology.

[35]  G. Canonica,et al.  Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs , 2016, Current opinion in allergy and clinical immunology.

[36]  R. Mirimanoff,et al.  Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial , 2015, The Lancet.

[37]  F. Balkwill,et al.  Inflammation and cancer: advances and new agents , 2015, Nature Reviews Clinical Oncology.

[38]  G. Hämmerling,et al.  Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells , 2015, Nature Immunology.

[39]  S. J. Henley,et al.  Patterns in lung cancer incidence rates and trends by histologic type in the United States, 2004-2009. , 2014, Lung cancer.

[40]  Fumihiro Tanaka,et al.  Recurrence after surgery in patients with NSCLC. , 2014, Translational lung cancer research.

[41]  C. Garlanda,et al.  Tumor associated macrophages and neutrophils in tumor progression , 2013, Journal of cellular physiology.

[42]  D. Talwar,et al.  Optimization of the systemic inflammation‐based Glasgow Prognostic Score , 2013, Cancer.

[43]  Stefan Michiels,et al.  Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  S. Lang,et al.  Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology , 2012, Cancer Immunology, Immunotherapy.

[45]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[46]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[47]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[48]  D. Coit,et al.  High neutrophil‐to‐lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD‐1 inhibitor monotherapy , 2019, Cancer.

[49]  Juanita Lopez,et al.  Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors. , 2018, European journal of cancer.

[50]  M. Kris,et al.  Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. , 2014, The Lancet. Oncology.

[51]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.